Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Healthtrust
Argus Health
Moodys
McKinsey
Merck

Generated: June 24, 2019

DrugPatentWatch Database Preview

LUVOX CR Drug Profile

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which patents cover Luvox Cr, and what generic alternatives are available?

Luvox Cr is a drug marketed by Jazz Pharms and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twenty-four patent family members in eighteen countries.

The generic ingredient in LUVOX CR is fluvoxamine maleate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the fluvoxamine maleate profile page.

Drug patent expirations by year for LUVOX CR
Synonyms for LUVOX CR
(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; but-2-enedioic acid
(E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)-1-pentanone O-(2-aminoethyl)oxime (Z)-2-butenedioate (1:1)
(E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate
(E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl)oxime maleate
(E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl)-1-pent
(E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime Maleate
(E)-5-Methoxy-1-[4-(triflurormethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime Maleate
(E)-Fluvoxamine Maleate
(Z)-2-butenedioic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
(Z)-but-2-enedioic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
(Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1)
1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime,(E)-, (Z)-2-butenedioate (1:1)
2-[({(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine (2Z)-but-2-enedioate
5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1)
5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate
54739-18-3
54739-18-3 (Parent)
54739-20-7
5LGN83G74V
61718-82-9
739F183
A833394
AB2000054
AC-9541
AKOS015961142
AN-39241
AS-11790
AX8016087
BG0368
C15H21F3N2O2.C4H4O4
C19H25F3N2O6
CCG-213494
CHEBI:5139
CHEMBL1409
CPD000466268
CS-1839
D00824
Depromel
DTXSID3042558
DU-23000
DU23000
Dumirox
EU-0100495
F 2802
F0858
Faverin
Fevarin
Floxyfral
Fluvoxamine (maleate)
Fluvoxamine for system suitability, European Pharmacopoeia (EP) Reference Standard
FLUVOXAMINE MALEATE
Fluvoxamine maleate (JP17/USAN)
Fluvoxamine maleate [USAN:USP]
Fluvoxamine maleate [USAN]
Fluvoxamine maleate, 1.0 mg/mL in methanol ((as free base)), certified reference material
Fluvoxamine maleate, British Pharmacopoeia (BP) Reference Standard
Fluvoxamine maleate, European Pharmacopoeia (EP) Reference Standard
Fluvoxamine Maleate, Pharmaceutical Secondary Standard; Certified Reference Material
Fluvoxamine maleate, solid
Fluvoxamine maleate, United States Pharmacopeia (USP) Reference Standard
HMS1571G11
HMS2098G11
HMS3261D11
HMS3715G11
HY-B0103A
J90043
KB-209260
LS-102000
Luvox
Luvox (TN)
maleic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
Maveral
MK-264
MLS000028469
MLS000758271
MLS001076285
MLS001304717
MLS001401391
MolPort-003-666-870
NCGC00093897-01
NCGC00093897-02
NCGC00261180-01
NSC 309469
NSC-309469
NSC-759602
NSC309469
NSC759602
Pharmakon1600-01505604
s1336
SAM001246977
SCHEMBL35225
SME 3110
SME-3110
SMR000058449
SMR000466268
SMR000653482
SR-01000075613
SR-01000075613-1
SR-01000075613-3
SR-01000075613-4
SR-01000075613-6
ST24035070
TL8003932
Tox21_500495
UNII-5LGN83G74V

US Patents and Regulatory Information for LUVOX CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jazz Pharms LUVOX CR fluvoxamine maleate CAPSULE, EXTENDED RELEASE;ORAL 022033-001 Feb 28, 2008 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Jazz Pharms LUVOX CR fluvoxamine maleate CAPSULE, EXTENDED RELEASE;ORAL 022033-002 Feb 28, 2008 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for LUVOX CR
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Capsules 100 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release 150 mg ➤ Subscribe ➤ Try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Teva
AstraZeneca
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.